Skip to main content
Premium Trial:

Request an Annual Quote

Iconix Signs DrugMatrix Deals with Lilly and FDA s Interdisciplinary Pharmacogenomic Review Group

NEW YORK, Nov. 17 (GenomeWeb News) - Iconix Pharmaceuticals has licensed its DrugMatrix chemogenomics system and Drug Signatures library to Elli Lilly and renewed a deal with the US Food and Drug Administration for the DrugMatrix system, the firm said today.


Under the agreement with Lilly, Iconix will add new compounds and tissues to DrugMatrix and identify additional Drug Signatures for those new domains. Lilly will integrate its in-house toxicogenomics data with DrugMatrix.


The agreement is similar to ones Iconix has in place with Bristol-Myers Squibb and Abbott.


Under the deal with the FDA, the agency's Center for Drug Evaluation and Research renewed its DrugMatrix agreement. The FDA installed DrugMatrix originally in March 2003 to use genomic markers to profile drug effects.


Under the renewal, Iconix will provide DrugMatrix to the FDA's Interdisciplinary Pharmacogenomic Review Group to evaluate genomic data submitted under the new data submission guidelines.

The Scan

Shape of Them All

According to BBC News, researchers have developed a protein structure database that includes much of the human proteome.

For Flu and More

The Wall Street Journal reports that several vaccine developers are working on mRNA-based vaccines for influenza.

To Boost Women

China's Ministry of Science and Technology aims to boost the number of female researchers through a new policy, reports the South China Morning Post.

Science Papers Describe Approach to Predict Chemotherapeutic Response, Role of Transcriptional Noise

In Science this week: neural network to predict chemotherapeutic response in cancer patients, and more.